Overview

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease. The study will also investigate reduction in daily pain in children who have sickle cell disease.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborators:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Prasugrel Hydrochloride